Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for preventing and curing H1N1 flu virus by adopting 4 (3H) quinazolone

An influenza virus, H1N1 technology, applied in the field of drugs to prevent and treat H1N1 influenza virus, can solve the problems of emergence of drug-resistant strains, large side effects, and poor tolerance of the elderly

Inactive Publication Date: 2009-10-14
LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the variation of influenza virus antigens and objective problems in the use of vaccines, the preventive effect of vaccines is only 70% to 90%.
In addition, the only clinically available anti-influenza drugs - amantadine and rimantadine, but they are only effective for influenza A, not effective for influenza B, and once the symptoms appear, the therapeutic effect is not very good; The side effects are relatively large, the elderly are not easy to tolerate, and it is easy to cause the emergence of drug-resistant strains, which limits its application
The broad-spectrum antiviral drug ribavirin can alleviate the clinical symptoms of influenza A and B, but it has not been approved by the FDA for the treatment of influenza because of its large side effects and the possibility of teratogenicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for preventing and curing H1N1 flu virus by adopting 4 (3H) quinazolone
  • Drug for preventing and curing H1N1 flu virus by adopting 4 (3H) quinazolone
  • Drug for preventing and curing H1N1 flu virus by adopting 4 (3H) quinazolone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 14

[0122] The preparation of embodiment 14 (3H) quinazolon tablet

[0123] 4 (3H) quinazolones and the weight ratio of each auxiliary material consumption are as follows:

[0124] 4(3H)quinazolone 1 part

[0125] 1 part microcrystalline cellulose

[0126] Calcium hydrogen phosphate 8 parts

[0127] 10% starch slurry 4 parts

[0128] starch 2 parts

[0129] Carboxymethyl starch sodium 0.4 parts

[0130] Magnesium stearate 0.3 parts

[0131] Preparation method: Folium folium pulverization (40 mesh) - heat reflux with 10 times the amount of 5% ethanol irradiated by microwave (109W) for 10 minutes - concentration - purification (the content of 4(3H) quinazolones is greater than 85%) - drying - crushing and sieving - adding excipients (calcium hydrogen phosphate, starch, microcrystalline cellulose, 10% starch slurry, sodium starch glycolate) - mixing - granulation - drying - granulation - lubricant (magnesium stearate) - mixing - Tablet coating - Packaging

Embodiment 24

[0132] The preparation of embodiment 24 (3H) quinazolon oral liquid

[0133] 4 (3H) quinazolones and the weight ratio of each auxiliary material consumption are as follows:

[0134] Element

[0135] Preparation method: Pulverize Folium Folium (40 mesh) - heat reflux with 10 times the amount of 5% ethanol irradiated by microwave (109W) for 10 minutes - concentration - refining and purification (4(3H) quinazolones content is greater than 85%) - immersion Paste-alcohol precipitation-green paste-water precipitation-adding excipients (purified water, sucrose, honey, sodium benzoate (preservative))-preparation-filtration-filling

Embodiment 34

[0136] The preparation of embodiment 34 (3H) quinazolon granules

[0137] 4 (3H) quinazolones and the weight ratio of each auxiliary material consumption are as follows:

[0138] Element

[0139] Preparation method: Pulverized Folium Folium (40 mesh) - heat reflux with 10 times the amount of 5% ethanol irradiated by microwave (109W) for 10 minutes - concentration - refining (4(3H) quinazolones content is greater than 85%) - adding Excipient sucrose-mixing-soft material-adding excipient dextrin-granulation-drying-adding excipient tartrazine-mixing-packaging

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug for preventing and curing H1N1 flu virus by adopting 4 (3H) quinazolone, which relates to the field of drugs for preventing and curing flu, the chemical synthetic drugs for resisting flue virus which are more ideal at present have low selectivity, large adverse reaction and high price and are easy to generate drug resistance after long-term use. The drug adopts monomeric compound 4 (3H) quinazolone extracted from dyers woad leaves; animal experiments, in vitro experiments and clinical experiments show that the drug has good effect of resisting flu virus, wide adaptability, rich drug sources, low cost and low toxic side effects and is not easy to generate drug resistance; the produced dosage forms are tablets, oral liquid and granular formulation; the clinical application dosage of the adult body is 60mg / 60Kg, and the drug is taken for 2-3 times everyday and continuously taken for 5 days.

Description

technical field [0001] The invention relates to the field of drugs for preventing and treating H1N1 influenza virus. Background technique [0002] Influenza is an acute viral respiratory infectious disease that endangers human life and health. There are large-scale outbreaks and epidemics in winter and spring every year. The main preventive measure against influenza at this time is vaccination. Due to the variation of influenza virus antigens and the objective problems in the use of vaccines, the preventive effect of vaccines is only 70% to 90%. In addition, the only clinically available anti-influenza drugs - amantadine and rimantadine, but they are only effective for influenza A, not effective for influenza B, and once the symptoms appear, the therapeutic effect is not very good; The side effects are large, the elderly are not easy to tolerate, and it is easy to cause the emergence of drug-resistant strains, which limits its application. The broad-spectrum antiviral dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/517A61P31/12A61P11/00
Inventor 梁剑平王曙阳王学红徐涛蒲秀英尚若峰郭文柱郭志廷刘宇郭延生华兰英
Owner LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com